SCHEMBL3869825

SCHEMBL3869825

CC(C)(C)OC(=O)c1c(N)cccc1C(=O)ON1C(=O)CC(O)C1=O

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.33
ALDH1A1 P00352 4/20 0.32
KDM4E B2RXH2 4/20 0.32
HPGD P15428 3/20 0.32
GLA P06280 2/20 0.32
GAA P10253 2/20 0.32
HSD17B10 Q99714 2/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
ELANE P08246 4/20 0.32
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
HIF1A Q16665 1/20 0.31
CFTR P13569 1/20 0.31
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL976497 0.72 MMP2 (0.47) GRM6ALDH1A1KDM4EHPGDGLA
SCHEMBL9269293 0.72 GRM6 (0.38) GRM6ALDH1A1KDM4EHPGDGLA
SCHEMBL2730411 0.72 GRM6 (0.49) GRM6ALDH1A1KDM4EHPGDGLA
SCHEMBL27651123 0.71 GRM6 (0.42) GRM6ALDH1A1KDM4EHPGDGLA
SCHEMBL6995362 0.71 ALDH1A1 (0.53) GRM6ALDH1A1KDM4EHPGDGLA
SCHEMBL9269299 0.71 SMN1; SMN2 (0.36) GRM6ALDH1A1KDM4EHSD17B10CFTR
SCHEMBL3869823 0.70 HDAC3 (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL4747442 0.68 ALDH1A1 (0.37) ALDH1A1KDM4EGAA
SCHEMBL25063427 0.68 ADRA1A (0.41) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL6577373 0.67 GRM6 (0.43) GRM6ALDH1A1KDM4EHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538182-B2 Polypeptide and protein derivatives and process for their preparation AMYLIN PHARMACEUTICALS, INC. (US) 2009-05-26 US disclosed
US-20070037967-A1 conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer AMYLIN PHARMACEUTICALS, INC. (US) 2007-02-15 US disclosed
US-7129327-B2 Polypeptide and protein derivatives and process for their preparation AMYLIN PHARMACEUTICALS, INC. (US) 2006-10-31 US disclosed
US-20040081660-A1 Polypeptide and protein derivatives and process for their preparation AMYLIN PHARMACEUTICALS, INC. 2004-04-29 US disclosed
US-6673347-B1 CONJUGATED TO POLYMER VIA SCHIFF BASE, HYDRAZONE, OXIME, OR AZOMETHINE COMPOUND; DIAGNOSING TUMORS AND METASTASIS GRYPHON THERAPEUTICS 2004-01-06 US disclosed
EP-0243929-B1 Polypeptide and protein derivatives and process for their preparation OFFORD ROBIN EWART (CH) 1995-09-27 EP disclosed
EP-0243929-A2 Polypeptide and protein derivatives and process for their preparation Offord, Robin Ewart (CH) 1987-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037967-A1 conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer HDGFL3, HCCS, HDGF GRM6 4628/4885ALDH1A1 3182/4885KDM4E 4779/4885
US-20040081660-A1 Polypeptide and protein derivatives and process for their preparation INSRR, GIPR, HM13 GRM6 3270/4885ALDH1A1 4808/4885KDM4E 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.